<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049282</url>
  </required_header>
  <id_info>
    <org_study_id>THYB-03</org_study_id>
    <nct_id>NCT01049282</nct_id>
  </id_info>
  <brief_title>A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)</brief_title>
  <acronym>THYB-03</acronym>
  <official_title>A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered in Different Antigen/Adjuvant Formulations in TST Negative and TST Positive Volunteers at 0 and 2 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has the following objectives:

      Primary objective To evaluate the safety profile of an adjuvanted TB subunit vaccine
      administered in different antigen/adjuvant formulations at 0 and 2 months Secondary objective
      To determine the immunogenicity profile of an adjuvanted TB subunit vaccine administered in
      different antigen/adjuvant formulations at 0 and 2 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of trial subjects=48 Investigational product=Ag85B - ESAT-6 + IC31 Dosage Group 1: TST
      negative, 50 µg antigen Group 2: TST negative, 50 µg antigen + fixed adjuvant Group 3: BCG
      vaccinated, 50 µg antigen + fixed adjuvant Group 4 : Latent TB, 50 µg antigen + fixed
      adjuvant Dosage volume 0.5 ml Administration Intramuscularly into deltoid muscle, alternate
      arms at day 0 (right) and day 56 (left).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety on Physical examination , and Laboratory safety tests of hematology clinical chemistry</measure>
    <time_frame>12 visits in a total of 224 days duratiion from the day of first vaccinantion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment by: A.Detection of IFN gama production after stimulation with Ag85B, ESAT-6 and H1. B.Detection of IgG antibodies to recombinant proteins Ag85B, ESAT-6 and H1 in serum/plasma.</measure>
    <time_frame>12 visits in a total of 224 days duratiion from the day of first vaccinantion</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>12 TST negative volunteers antigen only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 TST negative volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 BCG vaccinated volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 with Latent TB infection &gt;= 2 years ago</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antigen (Ag85B-ESAT-6)</intervention_name>
    <description>Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval</description>
    <arm_group_label>12 TST negative volunteers antigen only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antigen (Ag85B-ESAT-6) with adjuvant (IC31)</intervention_name>
    <description>Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval</description>
    <arm_group_label>12 TST negative volunteers</arm_group_label>
    <arm_group_label>12 BCG vaccinated volunteers</arm_group_label>
    <arm_group_label>12 with Latent TB infection &gt;= 2 years ago</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18 and 40 years old

          -  TST negative groups: TST- and negative QuantiFERON-TB Gold In tube test

          -  BCG group: known to be BCG-vaccinated &gt; 2 years before(scar, vaccination card), TST+
             (&gt; 6 or any documented value &gt; 6 mm on medical file in the past), with no active,
             chronic or past TB disease as confirmed by chest X ray, negative QuantiFERON-TB Gold
             In Tube test and negative 6-day lymphocyte tests.

          -  Infection group: latent TB, TST+ ( = or &gt; 10 mm or documented = or &gt; 10 mm positive on
             medical file in the past), previously TB infected but with no active disease confirmed
             by chest X ray, may have received chemoprophylaxis but with no TB
             treatment/chemoprophylaxis within the preceding 2 years, positive QuantiFERON-TB Gold
             In Tube test and/or positive 6-day lymphocyte test.

          -  Healthy based on medical examination/history at the inclusion

          -  Signed informed consent

          -  Prepared to grant authorized persons access to the medical records

          -  The volunteer is likely to comply with instructions

        Exclusion Criteria:

          -  Confirmed active TB based on clinical evaluation(history, physical findings and
             investigations)

          -  Vaccinated with any vaccine 3 months before first vaccination

          -  Administration of immune modulating drugs (steroids, immunosuppressive drugs or
             immunoglobulins)

          -  HBV, HCV or HIV sero-positive

          -  Participation in other clinical trials

          -  Known hypersensitivity to any of the vaccine components

          -  Laboratory parameters outside of normal range considered clinically relevant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jemal Hussein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armauer Hansen Research Institue/AHRI/,Ethiopia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bang, Msc</last_name>
    <role>Study Director</role>
    <affiliation>Statens serum Institute/SSI/,Denamrk</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>adjuvanted TB subunit vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

